IGF1R and pancreatic neoplasm: For instance, in pancreatic cancer therapy, a Phase III clinical trial (NCT01231347) of Ganitumab—a monoclonal antibody inhibiting IGF-1R activity—combined with gemcitabine failed to improve patient survival rates (Fuchs et al., 2015).